CNS Pharmaceuticals to Participate in the 2024 Healthcare Virtual Summit Presented by Maxim Group LLC

Rhea-AI Summary

CNS Pharmaceuticals, Inc. (NASDAQ:CNSP), a biopharmaceutical company focused on developing novel treatments for brain and central nervous system cancers, has announced its participation in the 2024 Healthcare Virtual Summit presented by Maxim Group John Climaco, CEO of CNS Pharmaceuticals, will engage in a fireside chat on Wednesday, October 16th at 4:00 PM ET.

The summit will feature a series of presentations and interactive discussions with CEOs and key management from various healthcare sectors, including biotechnology, diagnostics, medical devices, and healthcare information technology. Maxim Senior Analysts will host these sessions and conduct several topical industry panels.

Interested participants can attend the virtual event by signing up for an M-Vest membership. Further updates about the summit will be provided to registered attendees.

Live webcast fireside chat on Wednesday, October 16^th at 4:00 PM ET

HOUSTON, TX / ACCESSWIRE / October 8, 2024 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced that John Climaco, CEO of CNS Pharmaceuticals, will participate in a fireside chat at the 2024 Healthcare Virtual Summit, presented by Maxim Group LLC on October 16,2024 at 4:00 PM ET.

Maxim Senior Analysts will host a wide range of biotechnology, diagnostic, medical device, and healthcare information technology companies in a series of presentations and interactive discussions with CEOs and key management. Additionally, Maxim plans to host several topical industry panels that promise to be timely and engaging. To attend, just sign up to become an M-Vest member and stay tuned for more updates.

Click Here to Reserve Your Seat.

About CNS Pharmaceuticals, Inc.
CNS Pharmaceuticals is a clinical-stage pharmaceutical company developing a pipeline of anti-cancer drug candidates for the treatment of primary and metastatic cancers of the brain and central nervous system. The Company's lead drug candidate, Berubicin, is a novel anthracycline and the first anthracycline to appear to cross the blood-brain barrier. Berubicin is currently in development for the treatment of a number of serious brain and CNS oncology indications including glioblastoma multiforme (GBM), an aggressive and incurable form of brain cancer.

For more information, please visit www.CNSPharma.com, and connect with the Company on X, Facebook, and LinkedIn.

CONTACTS:

Investor Relations Contact
JTC Team, LLC
Jenene Thomas
908.824.0775
CNSP@jtcir.com

SOURCE: CNS Pharmaceuticals, Inc.

View the original press release on accesswire.com

FAQ

When is CNS Pharmaceuticals (CNSP) participating in the 2024 Healthcare Virtual Summit?

CNS Pharmaceuticals (CNSP) is participating in the 2024 Healthcare Virtual Summit on Wednesday, October 16th at 4:00 PM ET.

Who will represent CNS Pharmaceuticals (CNSP) at the 2024 Healthcare Virtual Summit?

John Climaco, CEO of CNS Pharmaceuticals (CNSP), will represent the company in a fireside chat at the 2024 Healthcare Virtual Summit.

What is the focus of CNS Pharmaceuticals (CNSP)?

CNS Pharmaceuticals (CNSP) is a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system.

How can investors attend the 2024 Healthcare Virtual Summit featuring CNS Pharmaceuticals (CNSP)?

Investors can attend the 2024 Healthcare Virtual Summit by signing up to become an M-Vest member. Registration details are available through the event's website.